Implementation science for the prevention and treatment of HIV/AIDS

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 1, 2010, Pages

  Schackman, Bruce R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLEMENTATION SCIENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; REVIEW; SCIENCE; VERTICAL TRANSMISSION;

BIOMEDICAL RESEARCH; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 78449300998     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f9c1da     Document Type: Review

References (44)

1. National Institutes of Health. Clinical, operations and health services research training award for AIDS and TB. Available at: grants.nih.gov/ grants/guide/pa-files/PAR-08-155.html. Accessed March 27, 2010.
2. National Institutes of Health. Dissemination and implementation research in health. Available at: grants.nih.gov/grants/guide/pa-files/PAR-10-038. html. Accessed January 8, 2010.
3. Fogarty International Center. Implementation science and global health. Available at: https://meetings.fic.nih.gov/index.cfm?event=home&ID=315. Accessed March 27, 2010.
4. Pangea Global AIDS Foundation. Report From the Expert Consultation on Implementation Science Research: A Requirement for Effective HIV/ AIDS Prevention and Treatment Scale-Up. 2009. Available at: http:// pgaf.org/publications/118-report-on-implementation-science-research. Accessed September 29, 2010.
5. Schmid G. Operations Research at IAS 2009 Track D Report. Presented at: 5th IAS Conference on HIV Pathogenesis and Treatment; 2009; Cape Town, South Africa.
6. Eccles MP, Mittman BS. Welcome to implementation science Implement Sci. 2006;1:1.
7. Global Fund to Fight AIDS Tuberculosis and Malaria, UNICEF/UNDP/ World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Framework for Operations and Implementations Research in Health and Disease Control Programs. Geneva, Switzerland; 2008. Available at: http://www. theglobalfund.org/documents/me/FrameworkForOperationsResearch. pdf. Accessed September 29, 2010.
8. United States President's Emergency Plan for AIDS Relief. The US President's Emergency Plan for AIDS Relief: 5-year strategy; Annex: PEPFAR's contribution to the Global Health Initiative; 2009. Available at: http://www.pepfar.gov/documents/organization/133437.pdf. Accessed September 29, 2010.
9. Hirschhorn LR, Ojikutu B, Rodriguez W. Research for change: using implementation research to strengthen HIV care and treatment scale-up in resource-limited settings. J Infect Dis. 2007;196(Suppl 3):S516-S522.
10. Institute of Industrial Engineeers. About IIE. Available at: http:// www.iienet2.org/Details.aspx?id=282. Accessed March 27, 2010.
11. National Center for Research Resources. Clinical and translational science awards. Available at: http://www.ncrr.nih.gov/clinical-research- resources/ clinical-and-translational-science-awards/. Accessed January 8, 2010.
12. Dougherty D, Conway PH. The "3T's" road map to transform US health care: the "how" of high-quality care. JAMA. 2008;299:2319-2321.
13. Naik AD, Petersen LA. The neglected purpose of comparativeeffectiveness research. N Engl J Med. 2009;360:1929-1931.
14. Institute of Translational Health Sciences. About translational research. Available at: http://www.iths.org/about/translational. Accessed January 8, 2010.
15. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med. 2007;9:665-674.
16. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol. 2007;197(3 Suppl):S42-S55.
17. The Interagency Task Team (IATT) on Prevention of HIV Infection in Pregnant Women Mothers and their Children. Guidance on Global Scale-Up of the Prevention of Mother-to-Child Transmission of HIV. Geneva, Switzerland: World Health Organization; 2007.
18. Coetzee D, Stringer EM, Chi BH, et al. Evaluation of PMTCT coverage in four African countries: the PEARL study. (WELBD101). Presented at: 5th IAS Conference on HIV Pathogenesis and Treatment; July 22, 2009; Cape Town, South Africa.
19. Mate KS, Bennett B, Mphatswe W, et al. Challenges for routine health system data management in a large public programme to prevent motherto- child HIV transmission in South Africa. PLoS One. 2009;4:e5483.
20. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
21. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656.
22. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369:657-666.
23. WorldHealthOrganization.Male Circumcision and HIV Prevention Operations Research Implications. Report of an International Consultation June 21-22, 2007. Nairobi, Kenya; 2007. Available at: http://www.malecircumcision.org/ research/documents/ORReport2.pdf. Accessed September 29, 2010.
24. Kiggundu V,Watya S, Kigozi G, et al. The number of procedures required to achieve optimal competency with male circumcision: findings from a randomized trial in Rakai, Uganda. BJU Int. 2009;104:529-532.
25. Herman-Roloff A, Llewellyn E, Bailey R, et al. Using health facility assessment data to strategically roll-out male circumcision in Nyanza province, Kenya: a mixed method approach. (MOPDC1). Presented at: 5th IAS Conference on HIV Pathogenesis and Treatment; July 7, 2009; Cape Town, South Africa.
26. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777-813.
27. Rhodes T, Platt L, Sarang A, et al. Street policing, injecting drug use and harm reduction in a Russian city: a qualitative study of police perspectives. J Urban Health. 2006;83:911-925.
28. Vickerman P, Hickman M, Rhodes T, et al. Model projections on the required coverage of syringe distribution to prevent HIVepidemics among injecting drug users. J Acquir Immune Defic Syndr. 2006;42:355-361.
29. Foss AM, Watts CH, Vickerman P, et al. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh? Addiction. 2007;102:114-125.
30. Des Jarlais DC, Kling R, Hammett TM, et al. Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS. 2007;21(Suppl 8):S109-S114.
31. Wu Z, Luo W, Sullivan SG, et al. Evaluation of a needle social marketing strategy to control HIVamong injecting drug users in China. AIDS. 2007; 21(Suppl 8):S115-S122.
32. Krusi A, Wood E, Montaner J, et al. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21:4-9.
33. Wood E, Kerr T, Tyndall MW, et al. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22:1247-1256.
34. Long EF, Brandeau ML, Galvin CM, et al. Effectiveness and costeffectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20:2207-2215.
35. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103:1484-1492.
36. Wood E, Hogg RS, Kerr T, et al. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS. 2005;19:837-839.
37. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIVinfected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000;14:151-155.
38. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIVinfected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49:1433-1440.
39. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103:1828-1836.
40. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006; 43(Suppl 4):S173-S177.
41. Cunningham CO, Kunins HV, Roose RJ, et al. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22:1325-1329.
42. Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36:244-251.
43. Schackman BR, Merrill JO, McCarty D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S247-S253.
44. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006; 43(Suppl 4):S184-S190.